John Draper
Family Medicine · Aurora, CONPI 1174541817
Payments from drug & device makers
Across 84 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$255
- AbbVie$226
- Johnson & Johnson$202
- Novo Nordisk$171
- Boehringer Ingelheim$70
- Merck$63
- plus $441 from 19 others
What the payments were for
- Food & beverage$1,428100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $255 |
| AbbVie(2 entities) | 11 | $226 |
| Johnson & Johnson | 12 | $202 |
| Novo Nordisk | 10 | $171 |
| Boehringer Ingelheim | 4 | $70 |
| Merck | 4 | $63 |
| Pfizer | 4 | $59 |
| Amgen | 3 | $55 |
| Amarin Pharma, Inc. | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Lilly USA, LLC | 2 | $27 |
| Genentech USA, Inc. | 1 | $24 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| GSK | 1 | $15 |
| Bayer | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Gilead | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$1,428 in reported general payments places this provider in the 80th percentile of 2,079 family medicine providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ShingrixVaricella-Zoster Ge/As01b/Pf | 13 | $2,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKShingrix | $15 | $2,99513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,079 family medicine providers in Colorado.
Other family medicine in Aurora
- Timothy ColanderAurora$3.1M
- Matthew LewisAurora$960K
- Tamara OserAurora$288K
- Sean OserAurora$248K
- Sarah DavisAurora$26K
- Clint FlanaganDacono$7.6M
- Larry OdekirkCastle Rock$6.3M
- Ripley HollisterColorado Springs$5.5M
- Mia ScottDenver$993K
- Ethan LazarusDenver$688K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.